Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 09, 2020
TickeronGET DAILY SIGNALS
Walgreens (WBA, $38.60) misses Q3 earnings estimate

Walgreens (WBA, $38.60) misses Q3 earnings estimate

Walgreens Boots Alliance Inc. reported third quarter earnings that missed analysts' expectations. 

The retail/wholesale pharmacy company’s adjusted earnings for the three months ending in May came in at 83 cents per share, falling short of the Street consensus estimate of $1.18 per share. The EPS was also -43.5% lower from the same period last year.  

Revenues rose +0.1% year-over-year to $34.6 billion, just ahead of analysts' estimates of a $34.35 billion.

Looking ahead, the company projected adjusted earnings in the region of $4.65 per share to $4.75 per share for the year, which  includes a coronavirus impact of between $1.03 and $1.14 per share. 

According to Tickeron, WBA in Downtrend: RSI indicator exits overbought zone

WBA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the ticker or exploring put options. In 21 of 29 cases where WBA's RSI Indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 72%.

Current price $38.50 is below $41.19 the lowest support line found by A.I. Throughout the month of 06/05/20 - 07/08/20, the price experienced a -7% Downtrend. During the week of 06/30/20 - 07/08/20, the stock fell -0.24%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 06, 2020. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 55 of 86 cases where WBA's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 64%.

The Moving Average Convergence Divergence (MACD) crossed below the signal line. In 36 of 52 cases where WBA's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 69%.

The 10-day Moving Average for this ticker crossed below its 50-day Moving Average on July 07, 2020. This can be construed as a sell signal, indicating that the trend is shifting lower. In 9 of 16 cases where WBA's 10-day Moving Average crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued Downtrend are 56%.

The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 21 of 35 cases where WBA's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 60%.

Bullish Trend Analysis

The Stochastic Indicator suggests the ticker price trend may be in a reversal from a Downtrend to an Uptrend. 31 of 61 cases where WBA's Stochastic Indicator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued Uptrend are 51%.

The price moved above its 50-day Moving Average, which indicates a change from a Downtrend to an Uptrend. In 27 of 45 similar backtested cases where WBA's price crossed above its 50-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 60%.

The Aroon Indicator entered an Uptrend today. In 61 of 181 similar cases where WBA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 34%.

Fundamental Analysis (Ratings)

Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 61%. During the last month, the daily ratio of advancing to declining volumes was 1.12 to 1.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. WBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.57) is normal, around the industry mean (2.94). P/E Ratio (10.87) is within average values for comparable stocks, (34.67). Projected Growth (PEG Ratio) (0.51) is also within normal values, averaging (0.57). Dividend Yield (3.47) settles around the average of (1.98) among similar stocks. P/S Ratio (0.29) is also within normal values, averaging (0.66).

Related Ticker: WBA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug store services

Industry DrugstoreChains

Industry
Drugstore Chains
Address
108 Wilmot Road
Phone
+1 847 315-3700
Employees
331000
Web
https://www.walgreensbootsalliance.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
Walgreens (WBA, $38.60) misses Q3 earnings estimate